Royal Bank of Canada Cuts Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $5.00

Inovio Pharmaceuticals (NASDAQ:INO) had its target price lowered by Royal Bank of Canada from $6.00 to $5.00 in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has a sector perform rating on the biopharmaceutical company’s stock.

INO has been the subject of a number of other research reports. HC Wainwright reiterated a “neutral” rating and issued a $3.00 price objective on shares of Inovio Pharmaceuticals in a research note on Wednesday. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Inovio Pharmaceuticals has a consensus rating of “Hold” and an average price target of $12.20.

Inovio Pharmaceuticals Stock Down 1.0 %

Shares of INO opened at $1.92 on Wednesday. The stock has a 50 day moving average price of $2.04 and a 200 day moving average price of $3.71. Inovio Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $14.75. The company has a market capitalization of $50.11 million, a price-to-earnings ratio of -0.91 and a beta of 0.92.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.18. The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.03 million. On average, equities analysts anticipate that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its stake in shares of Inovio Pharmaceuticals by 177.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 3,630 shares in the last quarter. MetLife Investment Management LLC grew its holdings in Inovio Pharmaceuticals by 129.1% in the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 8,546 shares during the last quarter. Alpine Global Management LLC purchased a new position in shares of Inovio Pharmaceuticals in the fourth quarter valued at $31,000. Atom Investors LP acquired a new position in shares of Inovio Pharmaceuticals during the 3rd quarter worth $103,000. Finally, Bank of Montreal Can acquired a new position in shares of Inovio Pharmaceuticals during the 4th quarter worth $43,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.